Traditional Chinese medicine compound preparation for reducing blood sugar and blood fat and preparation method of traditional Chinese medicine compound preparation

Abstract

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a traditional Chinese medicine compound preparation for reducing blood sugar and blood fat and a preparation method thereof.The monarch drug raw radix astragali has the effects of invigorating the spleen, tonifying qi and strengthening the root, the monarch drug cimicifugae foetidae-radix bupleuri is matched to construct a qi activity lifting hub, and the limitation that a traditional blood sugar reducing prescription purely nourishes yin and clears heat is broken through; a composite scheme of fire depression and simultaneous elimination of phlegm and blood stasis is adopted, iridoid components in cimicifugae foetidae promote M2 polarization of macrophages and reduce IL-1beta expression, a'body fluid production promoting and thirst quenching 'component taking puerarin as a carrier is combined with raw and cooked rehmannia root verbascoside to form an intestinal GLP-1 secretion enhancement effect, and meanwhile, the composition also has the characteristic of enhancing bioavailability; by optimizing the monarch, minister, assistant and guide relationship of the raw radix astragali, rhizoma atractylodis, rhizoma atractylodis macrocephalae and other medicinal materials, an intervention path of tonifying qi and yin and detoxifying and activating blood is established.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to a traditional Chinese medicine composite preparation for lowering blood sugar and blood lipids.

[0002] The present invention also relates to a method for preparing a traditional Chinese medicine composite preparation for lowering blood sugar and blood lipids. Background Art

[0003] Type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disease worldwide. Existing treatments have limited efficacy and safety risks. Currently, commonly used hypoglycemic drugs such as metformin and sulfonylureas can control blood sugar in the short term, but long-term use can easily lead to gastrointestinal reactions, hypoglycemia risk, and increased liver and kidney burden. In addition, single-target intervention is difficult to improve the core pathological factors such as insulin resistance and β-cell dysfunction. Existing traditional Chinese medicine prescriptions for the treatment of Qi and Yin deficiency diabetes, such as Liuwei Dihuang Wan and Yuquan San, generally have the following defects: (1) The composition combination focuses on nourishing Yin and clearing heat, but lacks consideration for the combined symptoms of spleen and kidney Yang deficiency; (2) The ratio of active ingredients is unclear, resulting in fluctuations in drug efficacy; (3) There is a lack of systematic design targeting modern pathological mechanisms such as intestinal flora regulation and insulin signaling pathway activation. Modern medicine often adopts staged symptomatic treatment for diabetic complications such as diabetic nephropathy and peripheral neuropathy, and lacks a comprehensive blockade of the "insulin resistance-oxidative stress-microcirculatory disorder" pathological chain. Secondly, Chinese herbal decoctions have problems such as being difficult to decoct and having a bitter taste, while Chinese patent medicine preparations generally have defects such as slow onset of effect and insufficient dosage standardization. Summary of the Invention

[0004] The purpose of the present invention is: to address the above-mentioned problems, the present invention provides a traditional Chinese medicine composite preparation for lowering blood sugar and blood lipids and a preparation method thereof. Through the synergistic effect of multiple components of traditional Chinese medicine, it can regulate glucose and lipid metabolism disorders while steadily lowering blood sugar, reduce drug-related toxic and side effects, and through the synergistic effect of core ingredients such as astragaloside IV and puerarin, simultaneously achieve blood sugar regulation, pancreatic beta cell protection and vascular endothelial repair. Through clinical retrospective analysis, blood sugar, glycosylated hemoglobin and blood lipids all decrease to varying degrees.

[0005] The technical solution adopted in the present invention is as follows: A traditional Chinese medicine compound preparation for lowering blood sugar and blood lipids comprises raw astragalus, atractylodes, white atractylodes, coix seed, prepared rehmannia root, raw rehmannia root, figwort, gardenia, coptis root, cimicifuga, bupleurum, kudzu root, salvia miltiorrhiza, and euphorbia pulex.

[0006] Furthermore, the raw astragalus is 30 parts, the atractylodes is 15 parts, the white atractylodes is 15 parts, the coix seed is 30 parts, the prepared rehmannia is 30 parts, the raw rehmannia is 30 parts, the Scrophularia is 30 parts, the gardenia is 15 parts, the coptis is 15 parts, the cimicifuga is 10 parts, the bupleurum is 15 parts, the kudzu root is 30 parts, the salvia miltiorrhiza is 30 parts, and the euphorbia pulex is 30 parts.

[0007] The second technical solution adopted by the present invention is a method for preparing a Chinese medicine compound preparation for lowering blood sugar and blood lipids, using a Chinese medicine compound preparation for lowering blood sugar and blood lipids, and the specific method includes: Crush raw astragalus, coix seed, coptis root, and salvia miltiorrhiza separately and mix them to obtain a mixed powder. Add clean water to the remaining herbs to ensure that they are completely soaked and in full contact with water, and then decoct them several times. The filtrate after decoction is filtered until it is clear and transparent, the residue is removed, and then the filtrate is concentrated until the remaining liquid becomes a thick clear paste, and then the mixed powder obtained by the previous crushing and an appropriate amount of dextrin are added and mixed evenly. After mixing evenly, the final composite preparation is obtained.

[0008] Furthermore, after pulverization, the powder was sieved using a 100-mesh sieve.

[0009] Furthermore, the decoction was performed three times, with the first decoction time being 2 hours, and the second and third decoction time being 1.5 hours respectively.

[0010] Furthermore, the filtrate is filtered separately after each decoction, and finally mixed and concentrated.

[0011] Furthermore, the filtrate is concentrated to a relative density of 1.25 to 1.30 at a temperature range of 60° C. to 80° C.

[0012] Furthermore, the compound preparation is prepared into tablets or pills.

[0013] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are: This invention discloses a novel traditional Chinese medicine compound formulation that can simultaneously lower both blood sugar and blood lipids. The finished product is available in pills or tablets. Based on the Traditional Chinese Medicine theory of "Qi Pivot" and the core pathogenesis of diabetes characterized by spleen deficiency, liver depression, and the interplay of phlegm, blood stasis, and fire toxins, this compound formulation provides a multi-target synergistic intervention. The main ingredient, Astragalus membranaceus, strengthens the spleen and replenishes Qi, while the auxiliary ingredients, Cimicifuga heracleifolia and Bupleurum chinense, establish a pivotal mechanism for Qi movement. This formulation transcends the limitations of traditional hypoglycemic formulas, which simply nourish Yin and clear heat. It employs a combination of "releasing fire depression" (a triangular combination of Gardenia jasminoides, Coptis chinensis, and Cimicifuga heracleifolia) and "eliminating phlegm and blood stasis" (a 1:1.5 herbal pairing of Radix Glehniae and Salvia miltiorrhizae). A concentration of ≥0.8 mg / g of iridoids in Cimicifuga heracleifolia promotes M2 macrophage polarization and reduces IL-1β expression. The "thirst-quenching" component, using puerarin as a carrier, combined with raw and cooked Rehmannia verbascoside, enhances intestinal GLP-1 secretion and bioavailability. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a comparative data chart of the therapeutic effects of 240 patients in the control group and the treatment group in the embodiment of the present invention; Figure 2 This is a data chart comparing the reduction in body mass index and waist-to-hip ratio in a clinical control experiment in an embodiment of the present invention; Figure 3 This is a comparative data diagram of the reduction of blood glucose monitoring indicators in a clinical control experiment in an embodiment of the present invention; Figure 4 This is a comparative data chart of the reduction of blood lipid monitoring indicators in a clinical control experiment in an embodiment of the present invention; Figure 5 This is a comparative data diagram of the reduction rate of atherosclerosis monitoring indicators in a clinical control experiment in an embodiment of the present invention; Figure 6 This is a comparison chart of clinical monitoring index levels before and after treatment based on a retrospective analysis in an embodiment of the present invention; Figure 7 A Venn diagram of the intersection targets of the Chinese medicine preparations and type 2 diabetes in the embodiments of the present invention; Figure 8 This is a drug-compound-target-disease network diagram in the embodiment of the present invention; Figure 9 This is a Sankey diagram of the drug sources of the TOP Chinese medicinal compounds in the Chinese medicinal preparations in the embodiments of the present invention; Figure 10 PPI interaction network diagram (left) and KEGG enrichment analysis (right) in the embodiment of the present invention; Figure 11 This is a compound-target-pathway-disease network diagram in the embodiments of the present invention; Figure 12 This is a diagram of the docking of the drug compound and the target AKT1 in the examples of the present invention. DETAILED DESCRIPTION

[0015] The present invention will be described in detail below with reference to the accompanying drawings.

[0016] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0017] The traditional Chinese medicine preparation Geqi Pingke Pill (Shaanxi medicine preparation code: Z20220184000) of the present invention establishes an intervention pathway of "invigorating qi and nourishing yin - detoxifying and activating blood circulation" by optimizing the monarch-minister-assistant-assistant relationship of 14 medicinal materials, including raw astragalus, atractylodes, and white atractylodes.

[0018] Example This embodiment provides a new Chinese medicine composite preparation that can lower blood sugar and blood lipids at the same time. The monarch ingredient of the composite preparation is raw Astragalus membranaceus, which has the effects of strengthening the spleen and replenishing qi, making qi vigorous and promoting the production of body fluid; the minister ingredients are Atractylodes lancea, Atractylodes macrocephala, and Coix seed, which have the effects of strengthening the spleen and drying dampness, removing dampness and lowering turbidity, and Cimicifuga heracleifolia and Bupleurum chinense, which have the effects of soothing the liver and relieving depression; the auxiliary ingredients are raw Rehmannia glutinosa, cooked Rehmannia glutinosa, and Scrophularia ningpoensis, which have the effects of nourishing the kidney and nourishing yin, nourishing yin and clearing heat, and Gardenia jasminoides and Coptis chinensis have the effect of clearing the fire stagnation in the liver and stomach; the envoys are Pueraria lobata, Euphorbia obesa, and Salvia miltiorrhiza, which respectively have the effects of invigorating the spleen and stomach, helping the spleen to promote the production of clear fluid and distribute body fluid, clearing heat and quenching thirst, promoting blood circulation and removing blood stasis, promoting blood circulation and removing blood stasis, clearing the heart and removing vexation, promoting menstruation and relieving pain, cooling blood and eliminating carbuncle.

[0019] The meaning of the Chinese medicine preparation in this embodiment is that the raw Astragalus invigorates the spleen and replenishes qi as the main medicine, Cangzhu and Coix Seed invigorate the spleen and dispel dampness, and Cimicifuga and Bupleurum soothe the liver and relieve depression, which are all ministerial medicines. The combination of the main and minister medicines strengthens the spleen and replenishes qi and dispels dampness, eliminating the source of phlegm and dampness. Phlegm and dampness are difficult to remove by conventional diuretics, dampness-removing and dampness-infiltrating drugs. Cimicifuga has the characteristics of promoting fire and dispersing dampness, and is also helpful in dispersing stubborn phlegm and dampness. After a long period of thirst, phlegm and dampness (fat toxicity), fire toxicity (sugar toxicity) and blood stasis (blood stasis) interact in the body. Cimicifuga combined with Bupleurum becomes the hub for regulating the body's qi, which promotes the smooth flow of qi, helps the spleen transport and transform, and is conducive to the removal of turbid phlegm and dampness. Raw and cooked Rehmannia nourishes the kidney and nourishes yin, Scrophularia nourishes yin and clears heat, Gardenia and Coptis chinensis clear liver and stomach fire, and Cimicifuga is used to "relieve fire stagnation." The combination of Pueraria root, Psoralea corylifolia, and Salvia miltiorrhiza promotes thirst-quenching, blood circulation, and unblocking the meridians, serving as guiding herbs. Spleen deficiency and liver depression are associated with Qi-tonifying and spleen-strengthening herbs, so they are combined with liver-soothing and depression-relieving herbs to suppress the liver and strengthen the spleen. This prescription focuses on regulating Qi, with the combined herbs working together to lower blood sugar, regulate lipids, and activate blood circulation and unblock the meridians, achieving comprehensive diabetes control.

[0020] The important preparation of the present embodiment has been used as a finished preparation and has shown a certain effect and curative effect for patients with type 2 diabetes with hyperlipidemia and fatty liver. The drug composition of the preparation of the present embodiment is 30g of Radix Astragali, 15g of Rhizoma Atractylodis Macrocephalae, 15g of Rhizoma Atractylodis Macrocephalae, 30g of Semen Coicis, 30g of Radix Rehmanniae Preparata, 30g of Radix Rehmanniae Preparata, 30g of Radix Scrophulariae, 15g of Fructus Gardeniae, 15g of Rhizoma Coptidis, 10g of Rhizoma Cimicifugae, 15g of Radix Bupleuri, 30g of Radix Puerariae, 30g of Radix Salviae Miltiorrhizae, 30g of Radix Pteris Pteris, a total of 14 Chinese medicines. The drug specification of the present embodiment is a Chinese medicine pill, and every 45 pills weigh 6 grams, 60g / bottle. Function and treatment are mainly to invigorate qi and nourish yin, and to detoxify and promote blood circulation. It is used for deficiency of both qi and yin, heat toxicity and blood stasis, and symptoms include obesity, fatigue, thirst and polyuria, red or dark tongue, thick or yellow fur, and stringy and slippery pulse. Usage and dosage 6-9g / time, 3 times / day, orally half an hour before meals. The treatment is suitable for patients with type 2 diabetes mellitus complicated by obesity, dyslipidemia, and insulin resistance as shown above. Contraindications include type 1 diabetes mellitus and type 2 diabetes mellitus with ketoacidosis.

[0021] Verification Example Two clinical trials of the Chinese medicine preparation of this embodiment were retrospectively analyzed. The first trial included 240 patients with type 2 diabetes mellitus who were diagnosed with type 2 diabetes mellitus accompanied by hyperlipidemia and fatty liver. The patients were randomly divided into two groups: a treatment group of 120 cases, including 72 males and 48 females, aged 44-74 years (60±13 years), 25 cases with eye lesions, 18 cases with cerebrovascular disease, and 48 cases with hypertension; a control group of 120 cases, including 68 males and 52 females, aged 48-73 years (60±11 years), 28 cases with eye lesions, 22 cases with cerebrovascular disease, 24 cases with hypertension, and 12 cases with prostatic hyperplasia; treatment method: The two groups of patients were divided into a control group and a treatment group. Both groups were routinely given metformin 0.5g + acarbose tablets 50mg three times a day, atorvastatin calcium 20mg once a day, and aspirin tablets 100mg once a day. Patients with hypertension were given nifedipine controlled-release 20mg once a day, orally; the treatment group was additionally given the Chinese medicine preparation of this example, one dose per day, decocted in water, twice a day, morning and evening; the treatment course for both groups was 12 weeks.

[0022] like Figure 1 As shown in the results, the total effective rate of treatment was 93.33% after 12 weeks of treatment, which was higher than the 76.67% of the control group, and the difference was statistically significant (P<0.05). Figure 2 、 Figure 3 、 Figure 4 and Figure 5 As shown, the overall effective rate (93.3%) was significantly improved after the addition of Geqi Pingke Pills to the drug group. The reduction in waist-to-hip ratio (41.0%) was also greater in the drug group than in the standard drug treatment group (33.3%). The largest difference in reductions in the drug treatment groups was in the reduction of blood glucose indicators, positively confirming that the Chinese medicine preparation in this example has a significant benefit in controlling blood glucose in patients with type 2 diabetes. In particular, the glycated hemoglobin (HbA1c) data, which reflects the average blood glucose level over three months, reached 48%. The drug group also had a significant effect on blood lipids, increasing high-density lipoprotein (HDL) and reducing cholesterol deposition in blood vessels. The reduction in low-density lipoprotein (LDL) was 4.1%, significantly higher than the 0.9% reduction in the control group, reducing atherosclerotic plaques and the risk of myocardial infarction and stroke. Furthermore, the drug group also saw a greater reduction in atherosclerosis indicators than the control group, including the dynamic arterial stiffness index (AASI) and carotid intima-media thickness (IMT).

[0023] Clinical data A total of 6,869 patients in the outpatient department of endocrinology and metabolism of a hospital were reviewed from August 2023 to 2024. According to the results of the previous case collection, the patients were divided into five subgroups for fasting blood glucose, glycosylated hemoglobin, serum total cholesterol, triglycerides, and low-density lipoprotein, and the effects of the Chinese medicine preparation on various indicators were explored, as shown in Table 1. Table 1 Retrospective analysis of the efficacy of the Chinese medicine preparations in this example in a certain hospital

[0024] like Figure 6 As shown, during the nearly one-year treatment period, the Chinese medicine preparation of this embodiment reduced fasting blood sugar by 16.3%, reduced glycosylated hemoglobin by 22.9%, reduced serum total cholesterol by 11.0%, reduced triglycerides by 26.8%, and reduced low-density lipoprotein by 19.1%. After processing with SPSS 27.0 software, the significance of each indicator before and after treatment was less than 0.05, indicating statistical differences. This proves that the Chinese medicine preparation of this embodiment also has the effect of lowering blood lipids on the basis of treating diabetes, and has obvious benefits for patients.

[0025] At the same time, network pharmacology research and analysis were also conducted on the Chinese medicine preparation in this embodiment, and relevant research on the intervention of the Chinese medicine preparation in this embodiment on type 2 diabetes was conducted using network pharmacology and molecular docking methods.

[0026] Collection of drug active ingredients and targets like Figure 7 As shown, TCMSP / HERB / ETCM were used to collect the chemical components of the Chinese medicine in the Chinese medicine preparation of this example, and the oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 were used as screening conditions to further screen out the active ingredients of the drugs. For the targets obtained from the database, the gene names of the drug targets were standardized and duplicated using the uniprot database, and finally the active ingredients and targets of the drugs were obtained, as shown in Table 2.

[0027] Table 2 Screened databases and addresses

[0028] Screening of drug and disease-related targets Disease-related targets were retrieved from the OpenTargets / CTD / Drugbank / GeneCards databases. Using the keyword "Diabetes mellitus type 2 T2DM," a summary of disease-related targets was retrieved. Gene names for disease targets were standardized and duplicated disease genes were removed. Potential disease targets were identified. A Venn diagram was then constructed to show the intersection of targets across different databases. The compound targets identified above were intersected with the disease targets downloaded from the databases in R. Common targets were identified as targets associated with drug therapy for the disease and used for further analysis. R 4.2.1, venndiagram 1.7.3, and upsetR 1.4.0 were used to display the Venn diagram and upset diagram, respectively, showing the intersection of targets across different databases.

[0029] Construction and analysis of drug-compound-target-disease networks like Figure 8 As shown in the figure, the one-to-one correspondence between active ingredients and targets was imported into Cytoscape 3.9.1 software to construct a drug-compound-target-disease network diagram. The nodes represent the compounds and targets, respectively, and the edges represent the interaction between the compounds and targets. The Network Analyzer plug-in was used to analyze the network topology and calculate the degree of the nodes.

[0030] Construction and analysis of protein-protein interaction networks The protein-protein interaction (PPI) network diagram was constructed using the STRING database. Intersection targets related to drug effects on diseases were imported into the STRING database. The species was selected as "Homo sapiens" and the confidence level was set to ≥0.7. The interaction relationships between proteins were obtained and saved as TSV and PNG files. The files were imported into Cytoscape software, and isolated targets without intersection were deleted. The network topology properties were analyzed, and core targets were screened based on the degree value ranking of the topological structure (cc / Bc / degree ranking). The core targets were screened using the Cytohubba plug-in Mcc algorithm.

[0031] GO function enrichment and KEGG pathway enrichment analysis like Figure 10As shown, active pharmaceutical ingredients and disease-related targets were subjected to gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis using the RclusterProfiler4.6.2 package. GO enrichment analysis was performed with a P<0.05 filter, and the top 20 biological terms with P values ​​less than 0.05 were selected for bar plotting. KEGG enrichment analysis was also performed with a P<0.05 filter, and the top 30 signaling pathways with P<0.05 were selected for visualization and bubble plotting.

[0032] Construction and analysis of drug-compound-target-pathway-disease networks like Figure 9 and Figure 11 As shown in the figure, to discover the potential mechanism of drug action, we selected core TOP pathways and their key targets and active ingredients, and constructed a "drug-compound-target-pathway-disease" network. This better demonstrates the interconnection between the important active ingredients and targets of drugs and certain important pathways, and their synergistic effects.

[0033] Molecular docking The selected key compounds were docked with the core target molecule. The 3D structure of the main active compound in the drug was downloaded from the Pubchem database, and the 3D structure of the core target protein was downloaded from the ProteinData Bank (https: / / www.rcsb.org / ). The core target protein was initially processed using Pymol 2.6.0 software to remove solvent molecules, and then further hydrogenated and charged using AutoDock Tools 1.5.7. The core target protein and active compound were saved as "pdbqt" format files, and the appropriate grid positions and sizes were set. Finally, Autodock Vina completed the docking of the component and target. The docking results were visualized using PyMOL software.

[0034] like Figure 12As shown, the final results show that the Chinese medicine preparation of the present invention has 165 potential targets for the intervention of type 2 diabetes, and the core targets are IL6, AKT1, TP53, TNF, IL1B, STAT3, EGFR, etc., involving the joint action of multiple pathways. By constructing a multi-level network of drug-target-disease, network pharmacology can reveal the mechanism of action, main targets and possible side effects of drugs, and can provide more in-depth mechanistic insights for real research, help researchers design real-world research and interpretation, and provide possible ideas for later basic experimental research. PI3K / AKT may be the main pathway for the "fat-sugar lipid complex" of the Chinese medicine preparation of the present invention to intervene in type 2 diabetes, involving mechanisms of action such as inflammation and apoptosis.

[0035] In summary, given the limitations of current Western and traditional Chinese medicine treatments, the advantages of the present invention are that it can simultaneously improve blood sugar, blood lipids, and blood pressure levels, has a certain therapeutic effect on fatty liver, and significantly improves body mass index and atherosclerosis. Therefore, the oral administration of the present traditional Chinese medicine preparation "Geqi Pingke Pills" in combination with basic treatment has a proven efficacy in treating diabetes and can effectively alleviate the progression of diabetic complications.

Claims

1. A Chinese medicine compound preparation for lowering blood sugar and blood lipids, characterized in that: The compound preparation comprises raw astragalus, atractylodes, white atractylodes, coix seed, prepared rehmannia root, raw rehmannia root, figwort, gardenia, coptis root, cimicifuga, bupleurum, kudzu root, salvia miltiorrhiza and euphorbia pulex.

2. A Chinese medicine composite preparation for lowering blood sugar and blood lipids according to claim 1, characterized in that: The raw astragalus root 30 parts, atractylodes 15 parts, white atractylodes 15 parts, coix seed 30 parts, prepared rehmannia root 30 parts, raw rehmannia root 30 parts, Scrophularia ningpoensis 30 parts, gardenia 15 parts, coptis chinensis 15 parts, cimicifuga 10 parts, bupleurum 15 parts, kudzu root 30 parts, salvia miltiorrhiza 30 parts, and euphorbia pulex 30 parts are prepared.

3. A method for preparing a Chinese medicine compound preparation for lowering blood sugar and blood lipids, using a Chinese medicine compound preparation for lowering blood sugar and blood lipids according to any one of claims 1 to 2, characterized in that: Specific methods include: Crush raw astragalus, coix seed, coptis root, and salvia miltiorrhiza separately and mix them to obtain a mixed powder. Add clean water to the remaining herbs to ensure that they are completely soaked and in full contact with water, and then decoct them several times. The filtrate after decoction is filtered until it is clear and transparent, the residue is removed, and then the filtrate is concentrated until the remaining liquid becomes a thick clear paste, and then the mixed powder obtained by the previous crushing and an appropriate amount of dextrin are added and mixed evenly. After mixing evenly, the final composite preparation is obtained.

4. The method for preparing a Chinese medicine composite preparation for lowering blood sugar and blood lipids according to claim 3, characterized in that: After pulverization, the powder was sieved using a 100-mesh sieve.

5. The method for preparing a Chinese medicine composite preparation for lowering blood sugar and blood lipids according to claim 3, characterized in that: Decoction is performed three times, the first decoction time is 2 hours, the second and third decoction time are 1.5 hours respectively.

6. The method for preparing a Chinese medicine composite preparation for lowering blood sugar and blood lipids according to claim 5, characterized in that: After each decoction, the filtrate is filtered separately and finally mixed and concentrated.

7. The method for preparing a Chinese medicine composite preparation for lowering blood sugar and blood lipids according to claim 5, characterized in that: The filtrate is concentrated to a relative density of 1.25 to 1.30 at a temperature range of 60° C. to 80° C.

8. The method for preparing a Chinese medicine composite preparation for lowering blood sugar and blood lipids according to any one of claims 3 to 7, characterized in that: The compound preparation is prepared into tablets or pills.

Images